- UBT251 is a triple agonist targeting GLP-1, GIP, and glucagon receptors.
- The phase 2 trial in China showed a 19.7% mean weight loss after 24 weeks.
- United Biotechnology and Novo Nordisk are jointly developing UBT251.
- A global phase 1b/2a trial by Novo Nordisk is expected to report data in 2027.
Trial Overview
UBT251, a triple agonist targeting GLP-1, GIP, and glucagon receptors, is being developed by United Biotechnology and Novo Nordisk. A phase 2 trial in China assessed its safety and efficacy in individuals with overweight or obesity.
Results
The trial demonstrated a statistically significant mean weight loss of up to 19.7% after 24 weeks, compared to 2.0% in the placebo group. Improvements were also noted in waist circumference, blood glucose, blood pressure, and lipids.
Safety Profile
UBT251 was found to have a safe and well-tolerated profile, with most adverse events being mild to moderate gastrointestinal issues that diminished over time.
Future Developments
Novo Nordisk has initiated a global phase 1b/2a trial to further investigate UBT251, with results expected in 2027. A phase 2 trial for type 2 diabetes is planned for the second half of 2026.
